<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>COX inhibitors reduce colorectal <z:mpath ids='MPATH_270'>adenoma</z:mpath> recurrence by up to 45% and <z:chebi fb="19" ids="27568">selenium</z:chebi> supplementation may prevent <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Following colonoscopic <z:mpath ids='MPATH_270'>adenoma</z:mpath> resection, 1,600 men and women, ages 40 to 80 years, were randomized to <z:chebi fb="0" ids="41423">celecoxib</z:chebi> (400 mg daily), a selective COX-2 inhibitor, and/or <z:chebi fb="19" ids="27568">selenium</z:chebi> (200 μg daily as selenized yeast), or double placebo </plain></SENT>
<SENT sid="2" pm="."><plain>The trial was initiated in November 2001 </plain></SENT>
<SENT sid="3" pm="."><plain>The primary trial endpoint is <z:mpath ids='MPATH_270'>adenoma</z:mpath> recurrence in each intervention group compared with placebo, as determined by surveillance colonoscopy conducted three to five years after baseline </plain></SENT>
<SENT sid="4" pm="."><plain>Randomization was stratified by use of low-dose aspirin (81 mg) and clinic site </plain></SENT>
<SENT sid="5" pm="."><plain>Following reports of cardiovascular toxicity associated with COX-2 inhibitors, the <z:chebi fb="0" ids="41423">celecoxib</z:chebi> arm was discontinued in December 2004 when 824 participants had been randomized </plain></SENT>
<SENT sid="6" pm="."><plain>Accrual continued with randomization to <z:chebi fb="19" ids="27568">selenium</z:chebi> alone or placebo </plain></SENT>
<SENT sid="7" pm="."><plain>Randomization of the originally planned cohort (n = 1,621) was completed in November 2008 </plain></SENT>
<SENT sid="8" pm="."><plain>A further 200 patients with one or more advanced <z:mpath ids='MPATH_270'>adenomas</z:mpath> (denoting increased risk for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>) were accrued to enhance statistical power for determining intervention efficacy in this higher-risk subgroup </plain></SENT>
<SENT sid="9" pm="."><plain>Accrual of the total cohort (n = 1,824) was completed in January 2011 </plain></SENT>
<SENT sid="10" pm="."><plain>Baseline cohort characteristics include: mean age 62.9 years; 65% male; body mass index (BMI) 29.1 ± 5.1; 47% taking low-dose aspirin while on trial; 20% with three or more <z:mpath ids='MPATH_270'>adenomas</z:mpath>; and 38% with advanced <z:mpath ids='MPATH_270'>adenomas</z:mpath> </plain></SENT>
<SENT sid="11" pm="."><plain>Intervention effects on <z:mpath ids='MPATH_270'>adenoma</z:mpath> recurrence will be determined, and their modification by genetic background and baseline <z:chebi fb="19" ids="27568">selenium</z:chebi> level </plain></SENT>
<SENT sid="12" pm="."><plain>The effect of <z:chebi fb="19" ids="27568">selenium</z:chebi> supplementation on risk for type II <z:mp ids='MP_0002055'>diabetes</z:mp> will also be reported </plain></SENT>
</text></document>